Patupilone (EPO906, Epothilone B)

Catalog No.S1364

Patupilone (EPO906, Epothilone B) Chemical Structure

Molecular Weight(MW): 507.68

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
In DMSO USD 250 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell MlrNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLiO3BtUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2yMYFlKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55N3WtNFYh|ryP NVvB[3VMW0GQR1XS
human A431 cell MnXFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfCN|RKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25Mlg3\S1yNjFOwG0> M4K5V3NCVkeHUh?=
human SW1710 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;VcmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPGVvMEWg{txO M3fWPXNCVkeHUh?=
human Daoy cell NF\QNoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn3TTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYpvwKwhUUN3ME2yMlc{\S1yNTFOwG0> NGDEOZNUSU6JRWK=
human BFTC-905 cell MkjLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NETyOWRKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OXWtNFUh|ryP NUXmeXEyW0GQR1XS
human A375 cell M{jhPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13ZT2wOUDPxE1? NWCyT4xXW0GQR1XS
human RKO cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUn1b3JiUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ4\S1yNTFOwG0> NVjJSHJzW0GQR1XS
human KYSE-510 cell NYG0XlV[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn21TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzinLUC1JO69VQ>? MYrTRW5ITVJ?
human HLE cell MnrCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwMk\lMVA2KM7:TR?= MoHjV2FPT0WU
human MCF7 cell NXzQ[XVQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG[y[5FKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> M4rONnNCVkeHUh?=
human 786-0 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGCwV3dKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOSCwTR?= M{S2S3NCVkeHUh?=
human TE-8 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNUBvVQ>? M2nHdHNCVkeHUh?=
ovarian carcinoma 1A9 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NU\KcXVtUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4Sgc5ZiemmjbjDjZZJkcW6xbXGgNWE6KGOnbHyg[5Jwf3Sq NHj5O|EyPjF|NEmyPC=>
human PANC-03-27 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWn2TGpSUW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|Ih|ryP NUHwVodvW0GQR1XS
human VMRC-RCZ cell NXHYWYpmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nYSWlvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|NjFOwG0> NEnCUGdUSU6JRWK=
human IGROV-1 cell NXvJTJdDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFO4[49KdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3NjFOwG0> M32yWHNCVkeHUh?=
human MG-63 cell MkPXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DMdGlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE3PSEQvF2= MnjBV2FPT0WU
human SIG-M5 cell MkDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUnJbnR{UW6qaXLpeIlwdiCxZjDoeY1idiCVSVetUVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4OTFOwG0> M2PLTnNCVkeHUh?=
human NCI-H650 cell M1P5SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIraPVZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNzFOwG0> NIHFd49USU6JRWK=
human PSN1 cell M2i0OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrVeXNKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE4OyEQvF2= MljwV2FPT0WU
human PA-1 cell NGrFS5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\QTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Qh|ryP MlnRV2FPT0WU
KB-8511 cells NE[yOXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PwTlczKGh? NXrVV4l4S2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3y[ZNqe3SjboSgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtPFUyOSCkeTC1NEBx\XKlZX70JEg4OiCqcjDlfJBwe3W{ZTmsJGlEPTB;MD6xPEDPxE1? NXuxdlljOTFzM{OwPFY>
KB-31 cells NFWxUVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGX4WIQ4OiCq NF\jbWlEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgeIhmKGe{b4f0bEBw\iCyYXPsbZRigGWuLYPlcpNqfGm4ZTDoeY1idiCncHnk[ZJud2mmIHPhdoNqdm:vYTDj[YxteyCNQj2zNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\Sl? M4LCOFEyOTN|MEi2
human BHY cell MoD5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjQ[pY6UW6qaXLpeIlwdiCxZjDoeY1idiCESGmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PSCwTR?= M2i5[XNCVkeHUh?=
human BB30-HNC cell NUfOXoRHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTwTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjBzIN88US=> NWfI[mh7W0GQR1XS
human HOS cell NYnPVW1ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{TDbWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVUh|ryP MY\TRW5ITVJ?
human 639-V cell NF76UllIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1n2NmlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQCEQvF2= M4nSdXNCVkeHUh?=
human ES1 cell  NFrUeGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGnoZVJKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlIyKM7:TR?= MlS4V2FPT0WU
human TE-15 cell  NICzc3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFrEXpVKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjVizszN MXnTRW5ITVJ?
human LXF-289 cell NEW3O3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4PyEQvF2= MWLTRW5ITVJ?
human CAL-12T cell NYP1W5E3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUjPdmpPUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNVJVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{mg{txO MXHTRW5ITVJ?
human T84 cell NX2xV4xMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV31Rm04UW6qaXLpeIlwdiCxZjDoeY1idiCWOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI1KM7:TR?= MnrYV2FPT0WU
human KYSE-450 cell NFvjfm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLHTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUS1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjZ5IN88US=> MlfmV2FPT0WU
human LCLC-103H cell MmThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYG4OnhTUW6qaXLpeIlwdiCxZjDoeY1idiCOQ1zDMVExO0hiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOxJI5O NXy0eYZjW0GQR1XS
human NCI-H810 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkO5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{IN88US=> MXPTRW5ITVJ?
human HUTU-80 cell NILy[3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLJPHJMUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkig{txO MVLTRW5ITVJ?
human NCI-H460 cell MoLzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGPFXJFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFYxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{Og{txO M{DkUnNCVkeHUh?=
human HGC-27 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3rnZWlvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzhizszN MkSxV2FPT0WU
human HSC-2 cell M4WyWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zVOWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3OyCwTR?= MkH1V2FPT0WU
human IA-LM cell NGj6VpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\qR4ZUUW6qaXLpeIlwdiCxZjDoeY1idiCLQT3MUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl|IN88US=> MmXtV2FPT0WU
human HMV-II cell M2XvWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2OydGlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN NH;1TJVUSU6JRWK=
human COLO-679 cell NGH0UVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4\YNGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7NDFOwG0> NInVTm5USU6JRWK=
human NCI-H2122 cell M3ezXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zCbWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0> MnLEV2FPT0WU
human CAL-39 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXiTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyOSEQvF2= M3fyRnNCVkeHUh?=
human SW954 cell MkDpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVfRV2FUUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDN4IN88US=> MVfTRW5ITVJ?
human LCLC-97TM1 cell NWiydppRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvOUfUUVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR2NDFOwG0> MXHTRW5ITVJ?
human KYSE-270 cell MoD6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMkewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDVizszN M3G2XXNCVkeHUh?=
human NB13 cell M376[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrHTY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60OFch|ryP NEHoNWRUSU6JRWK=
human SK-LMS-1 cell M3\QeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnVTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OTWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR4IN88US=> NYK3SIl7W0GQR1XS
human SW620 cell MkfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDuZ3pKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDhizszN M33ObHNCVkeHUh?=
human HCT-15 cell M1HOcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGK4[JhKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzF5IN88US=> MoXRV2FPT0WU
human DU-145 cell NUnMVJptT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= MX7TRW5ITVJ?
human ST486 cell MnTaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXhTY5pcWKrdHnvckBw\iCqdX3hckBUXDR6NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= MlXyV2FPT0WU
human A427 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYSzdYFlUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45OjhizszN MmDGV2FPT0WU
human HT-1080 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYD3R5RSUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NEKg{txO MlrjV2FPT0WU
human NCI-H2009 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHoTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh4MjFOwG0> Mny4V2FPT0WU
human SK-LU-1 cell MmjGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjnU453UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56Nk[g{txO NGnp[WFUSU6JRWK=
human SCC-4 cell M1;hb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVmwTmo6UW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDd5IN88US=> MV;TRW5ITVJ?
human NCI-H1299 cell NHnuNpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXZVopKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEig{txO Mn7xV2FPT0WU
human NH-12 cell MlTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWrJcohq[mm2aX;uJI9nKGi3bXHuJG5JNTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64PVEh|ryP M3P0XXNCVkeHUh?=
human SK-UT-1 cell NV\HWZJWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6OiEQvF2= NV\lN2gzW0GQR1XS
human Bel7402 MVLQdo9tcW[ncnH0bY9vKGG|c3H5 MofXO|IhcA>? Ml\vRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwQVAvQSEQvF2= NVH2dI1wOjJ|MkCzOVQ>
human A388 cell Ml\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4T6fmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVQh|ryP M4LlZnNCVkeHUh?=
human SW982 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLsfJRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QTlizszN M1TKV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
+ Expand

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
+ Expand
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Formulation: Dissolved in30% PEG-300
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) supplier | purchase Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) cost | Patupilone (EPO906, Epothilone B) manufacturer | order Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID